Events

Glasgow – Posters
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 and additional data on the cross-reactivity of the immune responses as part of two posters. 

Valencia – Posters
Delphine Guyon-Gellin, Chief Business Development Officer of Osivax, to provide a clinical update on OVX836 as part of a poster entitled “Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical Trial”. 

Florence Nicolas, Chief Development Officer and Co-founder of Osivax, to provide additional data on the cross-reactivity of the immune responses as part of a poster entitled “Cross-Reactivity of the Immune Response Triggered in a Phase 2 Study by a Novel, Broad-Spectrum Influenza Vaccine Candidate”.

Washington, DC – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Phase 2 immunogenicity results on OVX836 first-in-class broad-spectrum influenza vaccine in elderly patients”. 

Barcelona – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccin for broad-protection against multiple influenza strains”. 

Belfast – Oral Presentation and Posters
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide preclinical results obtained with OVX033 as part of a presentation entitled “OVX033, T-cell based vaccine targeting the nucleocapsid provides broad-spectrum protection against SARS-COV-2 VoC in Hamster challenge model”. Two more posters entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile” and “How to drastically improve influenza prevention: the addition of a T-cell component to increase current vaccine efficacy, preclinical and early clinical results” are also presented.

Oxford – Oral Presentation
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide latest clinical results obtained with OVX836 as part of a presentation entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile”. 

Washington DC – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccine for broad-protection against multiple influenza strains”. 

Virtual – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, a next generation universal Influenza vaccine focusing on T-Cell responses: Update on the clinical development plan”. 

Virtual – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”. 

Lyon – Oral Presentation
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”. 

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present the last clinical results of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Lyon – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled “the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine.”

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Lille – Oral Presentation
Florence Nicolas, Director of R&D and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza vaccine candidate: Short-term results of the Phase 1 clinical trial”.

Boston – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”.

Barcelona – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”.

Singapore – Oral Presentations and Posters
Alexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”. Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present “Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model”. Two more posters entitled “OVX836 protect ferrets in flu challenge study” and “OVX836 protection is mediated by CD8 T-cells as demonstrated in mice passive transfer studies” are also presented.